
## Ganesh Prasanna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/679401/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Understanding metabolism related differences in ocular efficacy of MGV354. Xenobiotica, 2021, 51, 5-14.	1.1	2
2	Application of Cell Impedance as a Screening Tool to Discover Modulators of Intraocular Pressure. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 269-281.	1.4	2
3	Using Healthcare Databases to Refine Understanding of Exploratory Associations Between Drugs and Progression of Openâ€Angle Glaucoma. Clinical Pharmacology and Therapeutics, 2019, 106, 874-883.	4.7	13
4	Glaucoma - Next Generation Therapeutics: Impossible to Possible. Pharmaceutical Research, 2019, 36, 25.	3.5	32
5	The Discovery of (S)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin Acid, a Soluble Guanylate Cyclase Activator Specifically Designed for Topical Ocular Delivery as a Therapy for Glaucoma, Journal of Medicinal Chemistry, 2018, 61, 2552-2570.	-2-yl) <u>-</u> 5-me	thyl-1H-pyra
6	Binding of a glaucoma-associated myocilin variant to the αB-crystallin chaperone impedes protein clearance in trabecular meshwork cells. Journal of Biological Chemistry, 2018, 293, 20137-20156.	3.4	15
7	A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing. , 2018, 59, 1704.		19
8	A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma. American Journal of Ophthalmology, 2018, 192, 113-123.	3.3	15
9	A murine glaucoma model induced by rapid in vivo photopolymerization of hyaluronic acid glycidyl methacrylate. PLoS ONE, 2018, 13, e0196529.	2.5	19
10	A Compact Whole-Eye Perfusion System to Evaluate Pharmacologic Responses of Outflow Facility. , 2017, 58, 2991.		13
11	Effects of Rho Kinase Inhibitors on Intraocular Pressure and Aqueous Humor Dynamics in Nonhuman Primates and Rabbits. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 355-364.	1.4	20
12	Pharmacology of novel intraocular pressure-lowering targets that enhance conventional outflow facility: Pitfalls, promises and what lies ahead?. European Journal of Pharmacology, 2016, 787, 47-56.	3.5	16
13	Effect of PF-04217329 a prodrug of a selective prostaglandin EP2 agonist on intraocular pressure in preclinical models of glaucoma. Experimental Eye Research, 2011, 93, 256-264.	2.6	51
14	Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating Prostaglandin F2α agonist, in preclinical models. Experimental Eye Research, 2011, 93, 250-255.	2.6	103
15	Correlation of <i>In Vitro</i> and <i>In Vivo</i> Kinetics of Nitric Oxide Donors in Ocular Tissues. Journal of Ocular Pharmacology and Therapeutics, 2009, 25, 105-112.	1.4	28
16	Corneal Neovascularization and Ocular Irritancy Responses in Dogs Following Topical Ocular Administration of an EP4-Prostaglandin E <sub>2</sub> Agonist. Toxicologic Pathology, 2009, 37, 911-920.	1.8	16
17	Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models. Experimental Eye Research, 2009, 89, 608-617.	2.6	36